FDA panel votes against Capricor's Deramiocel for DMD heart disease

July 30, 2026 9:30 AM

An FDA advisory committee voted 9-3 against the effectiveness of Capricor Therapeutics' (NASDAQ: CAPR) Deramiocel for treating cardiomyopathy in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found